Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2020

01-12-2020 | Autism Spectrum Disorder | Case report

A pediatric patient with autism spectrum disorder and epilepsy using cannabinoid extracts as complementary therapy: a case report

Authors: Juliana Andrea Ponton, Kim Smyth, Elias Soumbasis, Sergio Andres Llanos, Mark Lewis, Wilhelm August Meerholz, Robert Lawrence Tanguay

Published in: Journal of Medical Case Reports | Issue 1/2020

Login to get access

Abstract

Background

The pharmacological treatment for autism spectrum disorders is often poorly tolerated and has traditionally targeted associated conditions, with limited benefit for the core social deficits. We describe the novel use of a cannabidiol-based extract that incidentally improved core social deficits and overall functioning in a patient with autism spectrum disorder, at a lower dose than has been previously reported in autism spectrum disorder.

Case presentation

The parents of a 15-year-old boy, of South African descent, with autism spectrum disorder, selective mutism, anxiety, and controlled epilepsy, consulted a medical cannabis physician to trial cannabis extract to replace seizure medications. Incidentally, at a very low cannabidiol-based extract dose, he experienced unanticipated positive effects on behavioral symptoms and core social deficits.

Conclusion

This case report provides evidence that a lower than previously reported dose of a phytocannabinoid in the form of a cannabidiol-based extract may be capable of aiding in autism spectrum disorder-related behavioral symptoms, core social communication abilities, and comorbid anxiety, sleep difficulties, and weight control. Further research is needed to elucidate the clinical role and underlying biological mechanisms of action of cannabidiol-based extract in patients with autism spectrum disorder.
Literature
1.
go back to reference Zou M, Li D, Li L, Wu L, Sun C. Role of the endocannabinoid system in neurological disorders. Int J Dev Neurosci. 2019;76:95–102.PubMed Zou M, Li D, Li L, Wu L, Sun C. Role of the endocannabinoid system in neurological disorders. Int J Dev Neurosci. 2019;76:95–102.PubMed
3.
go back to reference Lai MC, Lombardo MV, Baron-Cohen S. Autism. Lancet. 2014;383(9920):896–910.PubMed Lai MC, Lombardo MV, Baron-Cohen S. Autism. Lancet. 2014;383(9920):896–910.PubMed
5.
go back to reference Jamain S, Quach H, Betancur C, Råstam M, Colineaux C, Gillberg IC, et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet. 2003;34(1):27–9.PubMedPubMedCentral Jamain S, Quach H, Betancur C, Råstam M, Colineaux C, Gillberg IC, et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet. 2003;34(1):27–9.PubMedPubMedCentral
6.
go back to reference Nguyen QA, Horn ME, Nicoll RA. Distinct roles for extracellular and intracellular domains in neuroligin function at inhibitory synapses. Elife. 2016;5:e19236.PubMedPubMedCentral Nguyen QA, Horn ME, Nicoll RA. Distinct roles for extracellular and intracellular domains in neuroligin function at inhibitory synapses. Elife. 2016;5:e19236.PubMedPubMedCentral
7.
go back to reference Yenkoyan K, Grigoryan A, Fereshetyan K, Yepremyan D. Advances in understanding the pathophysiology of autism spectrum disorders. Behav Brain Res. 2017;331:92–101.PubMed Yenkoyan K, Grigoryan A, Fereshetyan K, Yepremyan D. Advances in understanding the pathophysiology of autism spectrum disorders. Behav Brain Res. 2017;331:92–101.PubMed
9.
go back to reference Posey DJ, McDougle CJ. Pharmacotherapeutic management of autism. Expert Opin Pharmacother. 2001;2(4):587–600.PubMed Posey DJ, McDougle CJ. Pharmacotherapeutic management of autism. Expert Opin Pharmacother. 2001;2(4):587–600.PubMed
10.
go back to reference Goel R, Hong JS, Findling RL, Ji NY. An update on pharmacotherapy of autism spectrum disorder in children and adolescents. Int Rev Psychiatry. 2018;30(1):78–95.PubMed Goel R, Hong JS, Findling RL, Ji NY. An update on pharmacotherapy of autism spectrum disorder in children and adolescents. Int Rev Psychiatry. 2018;30(1):78–95.PubMed
12.
go back to reference Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456–73.PubMed Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456–73.PubMed
14.
go back to reference Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017;376(21):2011–20.PubMed Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017;376(21):2011–20.PubMed
15.
go back to reference Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome. N Engl J Med. 2018;378(20):1888–97.PubMed Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome. N Engl J Med. 2018;378(20):1888–97.PubMed
16.
go back to reference Babson KA, Sottile J, Morabito D. Cannabis, Cannabinoids, and Sleep: a Review of the Literature. Curr Psychiatry Rep. 2017;19(4):23. Babson KA, Sottile J, Morabito D. Cannabis, Cannabinoids, and Sleep: a Review of the Literature. Curr Psychiatry Rep. 2017;19(4):23.
17.
go back to reference Kurz R, Blaas K. Use of dronabinol ( delta-9-THC ) in autism: A prospective single-case-study with an early infantile autistic child. Cannabinoids. 2010;5(4):4–6. Kurz R, Blaas K. Use of dronabinol ( delta-9-THC ) in autism: A prospective single-case-study with an early infantile autistic child. Cannabinoids. 2010;5(4):4–6.
18.
go back to reference Kruger T, Christophersen E. An Open Label Study of the Use of Dronabinol (Marinol) in the Management of Treatment-Resistant Self-Injurious Behavior in 10 Retarded Adolescent Patients. J Dev Behav Pediatr. 2006;27(5):441. Kruger T, Christophersen E. An Open Label Study of the Use of Dronabinol (Marinol) in the Management of Treatment-Resistant Self-Injurious Behavior in 10 Retarded Adolescent Patients. J Dev Behav Pediatr. 2006;27(5):441.
19.
go back to reference Bar-Lev Schleider L, Mechoulam R, Saban N, Meiri G, Novack V. Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy. Sci Rep. 2019;9(1):200.PubMedPubMedCentral Bar-Lev Schleider L, Mechoulam R, Saban N, Meiri G, Novack V. Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy. Sci Rep. 2019;9(1):200.PubMedPubMedCentral
20.
go back to reference Baron-Cohen S, Wheelwright S, Skinner R, Martin J, Clubley E. The autism-spectrum quotient (AQ): evidence from Asperger syndrome/high-functioning autism, males and females, scientists and mathematicians. J Autism Dev Disord. 2001;31(1):5–17.PubMed Baron-Cohen S, Wheelwright S, Skinner R, Martin J, Clubley E. The autism-spectrum quotient (AQ): evidence from Asperger syndrome/high-functioning autism, males and females, scientists and mathematicians. J Autism Dev Disord. 2001;31(1):5–17.PubMed
21.
go back to reference Richardson KA, Hester AK, McLemore GL. Prenatal cannabis exposure - The “first hit” to the endocannabinoid system. Neurotoxicol Teratol. 2016;58:5–14.PubMed Richardson KA, Hester AK, McLemore GL. Prenatal cannabis exposure - The “first hit” to the endocannabinoid system. Neurotoxicol Teratol. 2016;58:5–14.PubMed
22.
go back to reference Lafourcade M, Larrieu T, Mato S, Duffaud A, Sepers M, Matias I, et al. Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions. Nat Neurosci. 2011;14(3):345–50.PubMed Lafourcade M, Larrieu T, Mato S, Duffaud A, Sepers M, Matias I, et al. Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions. Nat Neurosci. 2011;14(3):345–50.PubMed
23.
go back to reference Schwarz R, Ramer R, Hinz B. Targeting the endocannabinoid system as a potential anticancer approach. Drug Metab Rev. 2018;50(1):26–53.PubMed Schwarz R, Ramer R, Hinz B. Targeting the endocannabinoid system as a potential anticancer approach. Drug Metab Rev. 2018;50(1):26–53.PubMed
24.
go back to reference Philpott HT, O’Brien M, McDougall JJ. Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis. Pain. 2017;158(12):2442–51.PubMedPubMedCentral Philpott HT, O’Brien M, McDougall JJ. Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis. Pain. 2017;158(12):2442–51.PubMedPubMedCentral
25.
go back to reference Wei D, Dinh D, Lee D, Li D, Anguren A, Moreno-Sanz G, et al. Enhancement of Anandamide-Mediated Endocannabinoid Signaling Corrects Autism-Related Social Impairment. Cannabis Cannabinoid Res. 2016;1(1):81–9.PubMedPubMedCentral Wei D, Dinh D, Lee D, Li D, Anguren A, Moreno-Sanz G, et al. Enhancement of Anandamide-Mediated Endocannabinoid Signaling Corrects Autism-Related Social Impairment. Cannabis Cannabinoid Res. 2016;1(1):81–9.PubMedPubMedCentral
26.
go back to reference Karhson DS, Krasinska KM, Dallaire JA, Libove RA, Phillips JM, Chien AS, et al. Plasma anandamide concentrations are lower in children with autism spectrum disorder. Mol Autism. 2018;9(1):1–6. Karhson DS, Krasinska KM, Dallaire JA, Libove RA, Phillips JM, Chien AS, et al. Plasma anandamide concentrations are lower in children with autism spectrum disorder. Mol Autism. 2018;9(1):1–6.
28.
go back to reference Thiele EA, Marsh ED, French JA, Mazurkiewicz MB, Benbadis SR, Joshi C, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085–96.PubMed Thiele EA, Marsh ED, French JA, Mazurkiewicz MB, Benbadis SR, Joshi C, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085–96.PubMed
29.
go back to reference Gould GG, Seillier A, Weiss G, Giuffrida A, Burke TF, Hensler JG, et al. Acetaminophen differentially enhances social behavior and cortical cannabinoid levels in inbred mice. Prog Neuro-Psychopharmacology Biol Psychiatry. 2012;38(2):260–9. Gould GG, Seillier A, Weiss G, Giuffrida A, Burke TF, Hensler JG, et al. Acetaminophen differentially enhances social behavior and cortical cannabinoid levels in inbred mice. Prog Neuro-Psychopharmacology Biol Psychiatry. 2012;38(2):260–9.
31.
go back to reference Mazahery H, Stonehouse W, Delshad M, Kruger MC, Conlon CA, Beck KL, et al. Relationship between long chain n-3 polyunsaturated fatty acids and autism spectrum disorder: Systematic review and meta-analysis of case-control and randomised controlled trials. Nutrients. 2017;9(2):1–32. Mazahery H, Stonehouse W, Delshad M, Kruger MC, Conlon CA, Beck KL, et al. Relationship between long chain n-3 polyunsaturated fatty acids and autism spectrum disorder: Systematic review and meta-analysis of case-control and randomised controlled trials. Nutrients. 2017;9(2):1–32.
Metadata
Title
A pediatric patient with autism spectrum disorder and epilepsy using cannabinoid extracts as complementary therapy: a case report
Authors
Juliana Andrea Ponton
Kim Smyth
Elias Soumbasis
Sergio Andres Llanos
Mark Lewis
Wilhelm August Meerholz
Robert Lawrence Tanguay
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2020
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-020-02478-7

Other articles of this Issue 1/2020

Journal of Medical Case Reports 1/2020 Go to the issue